National Registry and Cohort Study of Pulmonary Vascular Disease

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · May 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying pulmonary arterial hypertension (PAH), a condition that affects the blood vessels in the lungs and can make it hard for patients to breathe. The goal of the study is to gather information about what causes PAH, how it affects patients, the treatments they receive, and their overall health outcomes. This research will help create a registry for PAH patients in China, allowing for better tracking and understanding of the disease, which can inform future health policies and treatment approaches.

To participate in the trial, individuals need to have either recently been diagnosed with PAH or have a previous diagnosis. They must also have a specific measurement from a test called right heart catheterization, which shows that the pressure in their pulmonary arteries is above 20 mm Hg. Participants can expect to be part of a larger effort to collect important health information that can help improve care for people with PAH. The study is open to everyone regardless of age or gender, and it aims to support better treatments and outcomes for patients living with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed or previously diagnosed patients with PH.
• • Documentation of mean pulmonary arterial pressure (mPAP) \>20 mm Hg by right heart catheterization, performed at any time prior to study enrollment.
• Exclusion Criteria:
• • Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH.
• • Do not meet the required hemodynamic criteria for entry into the study.